Duopharma Biotech Berhad (KLSE:DPHARMA)

Duopharma Biotech Berhad Income Statement

Financials in millions MYR. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	886.92	813.7	704.73	696.72	639.18	569.9
Revenue Growth (YoY)	18.57%	15.46%	1.15%	9.00%	12.16%	-1.14%
Cost of Revenue	558.25	512.16	436.4	416.9	385.19	336.7
Gross Profit	328.67	301.54	268.33	279.82	253.98	233.2
Selling, General & Admin	212.25	202.02	182.72	186.59	165.78	150.81
Other Operating Expenses	0.29	0.7	2.8	0.81	-0.67	1.35
Operating Expenses	211.11	201.28	189.61	186.91	165.22	151.35
Operating Income	117.56	100.26	78.71	92.91	88.77	81.86
Interest Expense	-24.55	-25.77	-17.68	-9.1	-6.44	-6.53
Interest & Investment Income	5.7	5.97	2.75	1.52	1.2	1.51
Other Non Operating Income (Expenses)	-0.82	-0.82	-0.52	-0.48	-0.53	-0.68
EBT Excluding Unusual Items	97.89	79.63	63.27	84.85	82.99	76.16
Gain (Loss) on Sale of Assets	0.39	0.39	-	-	-0.01	-
Pretax Income	98.28	80.02	63.27	84.85	82.98	76.16
Income Tax Expense	21.76	17.38	10.62	14.74	17.3	17.55
Net Income	76.52	62.65	52.65	70.11	65.68	58.61
Net Income to Common	76.52	62.65	52.65	70.11	65.68	58.61
Net Income Growth	54.78%	19.00%	-24.91%	6.74%	12.07%	6.04%
Shares Outstanding (Basic)	961	962	959	948	928	928
Shares Outstanding (Diluted)	961	962	959	948	928	928
Shares Change (YoY)	-0.06%	0.36%	1.08%	2.15%	0.02%	3.86%
EPS (Basic)	0.08	0.07	0.05	0.07	0.07	0.06
EPS (Diluted)	0.08	0.07	0.05	0.07	0.07	0.06
EPS Growth	54.87%	18.57%	-25.71%	4.50%	12.05%	2.09%
Free Cash Flow	99.29	59.77	15.86	5.08	-66.16	15.24
Free Cash Flow Per Share	0.10	0.06	0.02	0.01	-0.07	0.02
Dividend Per Share	0.035	0.030	0.023	0.023	0.022	0.049
Dividend Growth	25.00%	30.44%	-	5.75%	-55.43%	8.44%
Gross Margin	37.06%	37.06%	38.07%	40.16%	39.74%	40.92%
Operating Margin	13.26%	12.32%	11.17%	13.33%	13.89%	14.36%
Profit Margin	8.63%	7.70%	7.47%	10.06%	10.28%	10.28%
Free Cash Flow Margin	11.20%	7.35%	2.25%	0.73%	-10.35%	2.67%
EBITDA	154.62	137.34	114.04	122.86	114.94	105.93
EBITDA Margin	17.43%	16.88%	16.18%	17.63%	17.98%	18.59%
D&A For EBITDA	37.05	37.08	35.32	29.95	26.18	24.08
EBIT	117.56	100.26	78.71	92.91	88.77	81.86
EBIT Margin	13.26%	12.32%	11.17%	13.33%	13.89%	14.36%
Effective Tax Rate	22.14%	21.72%	16.79%	17.37%	20.85%	23.04%

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.